Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 15Active not recruiting 6Recruiting 5Terminated 3Unknown 2Approved for marketing 2Withdrawn 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1

Conditions

Thyroid Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 3Radiotherapy, Intensity-Modulated 2Radiation 2pembrolizumab 1palbociclib 1lenvatinib 1gedatolisib 1dabrafenib 1cemiplimab 1atezolizumab 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Platinum 1Neck Dissection 1Everolimus 1Cisplatin 1Atorvastatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × lenvatinib × Head & Neck × Clear all
NCT03139747 2021-10-15

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Thomas Jefferson University

Phase 2 Suspended
5 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡